Funder: European Commission
Due Dates: September 16, 2025 (single-stage)
Funding Amounts: €9–13 million per project | ~3 projects funded | Project duration typically 4–5 years
Summary: Supports research to develop, manufacture, and clinically validate safe, effective human cell secretome-based therapies, advancing them toward regulatory approval and healthcare adoption.
Key Information: Consortium applications required; clinical trials (Phase 1 & 2) must be included; SMEs and EU deployment prioritized.